Amicus Therapeutics, Inc. (FOLD) Announces Chaperone-Advanced Replacement Therapy in Development for Mucopolysaccharidosis Type I (MPS I)  
6/25/2013 10:05:32 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

CRANBURY, N.J., June 25, 2013 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD) today disclosed a preclinical Chaperone-Advanced Replacement Therapy (CHARTâ„¢) program for Mucopolysaccharidosis Type I (MPS I), a lysosomal storage disease caused by missing or deficient alpha-L-iduronidase (IDUA) enzyme. Amicus is developing a proprietary human recombinant IDUA (rhIDUA) enzyme co-formulated with a novel pharmacological chaperone as a next-generation therapy for MPS I.

Help employers find you! Check out all the jobs and post your resume.